Comparing Two Injectable Forms of Cagrilintide With Placebo in Overweight or Obesity
Compares two injectable versions of cagrilintide with placebo in adults with overweight or obesity.
Plain-language title generated from the registry record
Registry title: A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
Key facts
- Where
- Athens, Iraklio (Kritis), Peristeri, and Thessaloniki, GreeceSee the 6 sites
- Phase
- Phase 3
Where in Greece
- General Hospital of Athens - AlexandraAthens, GreeceNo longer taking part
- General Hospital of Athens "G. Gennimatas"Athens, GreeceNo longer taking part
- General Hospital Venizeleio-PananeioIraklio (Kritis), GreeceNo longer taking part
- Athens Medical Center S.A.Peristeri, GreeceNo longer taking part
- Ippokratio General Hospital of ThessalonikiThessaloniki, GreeceNo longer taking part
- St. Luke's Hospital S.A.Thessaloniki, GreeceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07745504EU 2025-524249-29-00
- Record updated
- 4 September 2026
- Original description
The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.Read full original descriptionShow less
A Placebo-controlled Comparability Study to Compare Two Presentations of Cagrilintide for Weight Management in Participants With Overweight or Obesity
The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.
Inclusion: Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study; Male or female (sex assigned at birth, inclusive of all gender identities); Age 18 years or above at the time of signing the informed consent; Body mass index (BMI) greater than or equal to (>=) 30.0 kilograms per square meter (kg/m\^2), or BMI >= 27.0 kg/m\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.
Exclusion: Previous dosing of marketed or non-marketed amylin-based compounds; Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening; History of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D).